ACTU

Actuate Therapeutics, Inc. (ACTU) - Q3 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2025. Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing elraglusib, a GSK-3 inhibitor, for the treatment of various cancers. The company has no approved products and has not generated any revenue since inception. It is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses for the nine months ended September 30, 2025, decreased by $0.79 million compared to the same period in 2024. This was driven by a significant $6.83 million reduction in Research and Development (R&D) expenses, primarily due to lower external clinical trial costs and Chemistry, Manufacturing, and Control (CMC) costs. Conversely, General and Administrative (G&A) expenses increased by $6.03 million, largely due to higher personnel-related costs (including stock-based compensation) and professional fees.
• Net Loss: The net loss for the nine months ended September 30, 2025, improved by $3.17 million compared to the prior year period. This improvement is attributed to the reduction in operating expenses and the absence of non-cash losses related to the fair value changes of warrant liabilities and related party convertible notes that impacted the 2024 period.
• Liquidity: Cash balances increased by $8.28 million during the nine-month period, primarily due to significant financing activities, including a public offering and private placements.

Guidance, Outlook, and Risks

• Clinical Progress: Topline data from the Phase 2 Actuate-1801 trial in metastatic pancreatic ductal adenocarcinoma (mPDAC) met its primary endpoint, showing a statistically significant improvement in median overall survival (10.1 months vs. 7.2 months) and a 37% reduction in the risk of death. The company has filed for Breakthrough Therapy Designation (BTD) with the FDA.
• Capital Requirements & Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern. Based on current plans, cash on hand ($16.9 million) is expected to fund operations only through the second quarter of fiscal year 2026. Additional capital is required to continue clinical development and operations.
• Financing Activities: The company raised approximately $24 million in net proceeds during the nine months ended September 30, 2025, through:
  • A September 2025 underwritten public offering ($15.57 million).
  • A June 2025 private placement ($4.59 million).
  • Sales under a Committed Equity Facility with B. Riley ($3.80 million).
• Risks: Key risks include the inability to raise additional capital on acceptable terms, potential delays in regulatory approval, reliance on a single product candidate (elraglusib), and the speculative nature of clinical-stage biopharmaceutical development.

Investor Verification Checklist

• Verify the timeline and sufficiency of future capital raises required to reach the next major clinical or regulatory milestone, given the "substantial doubt" going concern warning.
• Confirm the FDA's response to the Breakthrough Therapy Designation (BTD) request and the specific data requirements for a potential Phase 3 trial or registration.
• Review the terms of the Committed Equity Facility with B. Riley, specifically the discount rate and potential dilution impact on existing shareholders.
• Monitor the enrollment and data readout of the planned Phase 2 study in Ewing sarcoma (EWS), identified as a potential second indication.
• Assess the impact of the 75-day lock-up period following the September 2025 public offering on stock liquidity and price stability.